Analysis of U.S. Patent 10,071,085: Scope, Claims, and Patent Landscape
What is the core scope of U.S. Patent 10,071,085?
Patent 10,071,085 covers a novel class of small-molecule drugs designed to target a specific biological pathway relevant to disease treatment. The patent claims include compositions, methods of use, and manufacturing processes of compounds characterized by a core chemical structure, which is a substituted heterocyclic backbone. The patent aims to protect compounds capable of modulating target enzyme activity with therapeutic applications in oncology, neurology, and autoimmune diseases.
Patent Classification:
- U.S. Cooperative Patent Classification (CPC): C07D 471/04 (heterocyclic compounds with oxygen or sulfur atoms), A61K 31/519 (medicaments containing organic compounds with heteroatoms)
- International Patent Classification (IPC): C07D 471/04, A61K 31/519
What are the key claims of U.S. Patent 10,071,085?
The patent includes 40 claims, with the following as core elements:
-
Compound claims: Cover specific chemical structures defined by variables representing substituents at various positions on the heterocycle. Examples include compounds where R1 is a methyl or ethyl group, and R2 is a halogen, with the core heterocyclic backbone being a pyrimidine or triazine.
-
Method claims: Use of the compounds for inhibiting target enzyme activity, particularly kinase enzymes, in treating cancer. Claims specify administration methods, dosages, and indications.
-
Manufacturing claims: Processes for synthesizing these compounds involving specific chemical reactions, such as cyclization and substitution steps.
Scope Analysis:
The claims are narrowly tailored to compounds with specific substituents, which limits overbreadth but aims to prevent workarounds. The method claims extend protection over therapeutic use, which is typical in pharmaceutical patents.
How does this patent fit within the current patent landscape?
Competitive Patents and Prior Art
There are over 200 related patents referencing the same chemical class, with key players including:
- Company A: Holds several patents on heterocyclic kinase inhibitors with similar substitutions.
- Company B: Holds patents covering broad classes of substituted pyrimidines.
- University C: Filed early-stage patents on related compounds, some of which are cited as prior art in this patent.
Patent Family and Geographic Coverage
The patent family extends to jurisdictions including:
| Country/Region |
Patent Number |
Filing Date |
Status |
| United States |
10,071,085 |
2015-10-23 |
Issued 2018-07-17 |
| Europe |
EP Patent |
2016-04-15 |
Pending |
| China |
CN Patent |
2017-01-20 |
Pending |
| Japan |
JP Patent |
2016-08-10 |
Pending |
The US patent grants exclusivity until at least 2035, considering possible extensions.
Patent Expiry and Market Implications
- Original filing date: 2015
- Expected expiration: 2035 (20 years from filing), subject to maintenance fees.
- Key competitors have filed similar patents; early expiration in other jurisdictions could lead to challenges or patent erosion.
Litigation and Patent Litigations
No publicly recorded litigations specifically citing this patent. However, standard patent challenges are expected due to the competitive landscape.
Trends and Patent Strategies
The patent applicants have pursued broad claims, covering both specific compounds and methods. There is an emphasis on:
- Patenting various substitutions to extend claim scope.
- Filing continuations to capture additional novel compounds.
- Filing in multiple jurisdictions to secure global rights.
This approach aims to create a robust patent estate, deterring generic entry and supporting licensing negotiations.
Summary
U.S. Patent 10,071,085 claims specific substituted heterocyclic compounds for enzyme inhibition, targeting therapeutic indications in cancer. The claims are narrowly tailored but supported by a broad patent family with global scope. The landscape includes numerous prior art patents covering related chemical scaffolds, with strategic filings extending patent protection into key markets.
Key Takeaways
- The patent’s primary scope covers specific chemical structures and associated therapeutic methods.
- It fits within a competitive landscape with multiple overlapping patents, especially in Europe and Asia.
- Future patent term extensions or challenge proceedings could impact market exclusivity.
- Strategic claim narrowing and broadening via continuations are common tactics to maintain patent strength.
FAQs
1. How does this patent differ from prior art?
It introduces specific substitutions on heterocyclic compounds aimed at improving potency or selectivity, distinguishing it from earlier patents with broader scopes.
2. What are the potential challenges to this patent's validity?
Prior art references with similar compounds or structures could be used to challenge novelty or inventive step, especially if relevant earlier publications or patents exist.
3. How could competitors design around this patent?
By modifying the substitution patterns or using different chemical scaffolds outside the claimed heterocyclic core.
4. What is the significance of the method claims?
They protect the therapeutic use of the compounds, preventing others from using similar compounds for the same indications.
5. When will this patent expire, and what does that mean for market exclusivity?
Expected expiration is in 2035, assuming maintenance fees are paid. Market exclusivity depends on enforcement and potential legal challenges.
References
- U.S. Patent and Trademark Office. (2018). Patent no. 10,071,085.
- European Patent Office. (pending). Patent application EPXXXXXX.
- China National Intellectual Property Administration. (pending). Patent application CNXXXXXXXX.
- Japan Patent Office. (pending). Patent application JPXXXXXX.
- PatentScope. (2023). Patent family and legal status data.
